Home » Newsletters » BioWorld Science

BioWorld Science

May 19, 2003

View Archived Issues

Safety and efficacy of bimosiamose in psoriasis

Efficacy of IDEC-114 in moderate to severe psoriasis does not reach statistical significance

Schering AG presents new estrogenic agents for contraception and cancer therapy

New PPAR modulators discovered by Novo Nordisk researchers

Novel KDR/Tie-2 inhibitors prepared and tested at Aventis

Indian team discovers new PPAR agonists with utility in diabetes, dyslipidemia, etc.

Dual NO donors/free radical scavengers under study at Merck KGaA

New orexin-1 antagonists and their use described in GSK patent

17Beta-HSD-3 inhibitors in early development at Schering-Plough

Thrombin receptor antagonists claimed by Schering-Plough

5-HT2C receptor ligands and their use in anxiety, obesity, depression, etc.

Stressgen presents preclinical data on CoVal fusion peptide targeting HBV

Preliminary phase II Onyvax-P results

Evidence of cytotoxic effects of IL-13-PE38QQR in brain cancer

Preclinical data support use of human neural stem cells in repairing nervous system

Medarex and Amrad to develop therapeutic antibodies

Teva and Eisai to codevelop rasagiline for Alzheimer's, copromote in U.S.

FDA committee recommends Valtrex for reduction of genital herpes transmission

Genmab completes phase IIb recruitment for HuMax-CD4 in psoriasis

ChemGenex completes enrollment in first part of Quinamed phase I/II trial

Evotec and Artesian enter CHF drug discovery agreement

Q1 progress at Titan

Aldurazyme launched for MPS I

RiboTargets merged into British Biotech

DOV-21947 enters clinical testing

Potent and selective inhibitor of LFA-1/ICAM-1 interaction for T-cell-dependent skin diseases

Phenolic-based topical antiinflammatory agent in development at Cutanix

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 31, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 31, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
Shionogi nabs revenue-generating ALS drugs with $2.5B Tanabe pact
BioWorld
Shionogi & Co. Ltd. will acquire global rights to U.S. FDA approved amyotrophic lateral sclerosis therapy edaravone through a $2.5 billion acquisition deal with...
Big pharma taps fast Asia innovation in search of next Keytruda
BioWorld
Speed and innovation from Asia Pacific’s (APAC) biotechnology sector had big pharma scouring the region for the next oncology heir to Keytruda (pembrolizumab),...